STEMI患者直接PCI后普拉格雷与氯吡格雷对心肌挽救的影响:伴或不伴高残留血小板反应性时的比较
本研究在854例接受直接PCI的STEMI患者中,对446例用两相SPECT评估心肌挽救指数(MSI)。按P2Y12抑制剂分为普拉格雷组227例、氯吡格雷无HRPR组109例和氯吡格雷伴HRPR组107例。氯吡格雷伴HRPR组MSI显著更低,普拉格雷相比伴HRPR的氯吡格雷与更高MSI相关。
要点
- 氯吡格雷伴高残留血小板反应性(HRPR)者SPECT评估的心肌挽救指数显著更低。
- 普拉格雷组相比氯吡格雷伴HRPR组心肌挽救指数更高。
- 氯吡格雷伴HRPR组最终TIMI 0/1血流和心肌灌注分级0/1发生率更高。
核心结论
- 在伴高残留血小板反应性的STEMI患者中,普拉格雷相比氯吡格雷与更高的心肌挽救指数相关。
研究设计与样本
- 研究纳入854例接受直接PCI的连续STEMI患者,其中446例接受7天和3个月两相SPECT评估。
- 按负荷P2Y12抑制剂分为普拉格雷组227例、氯吡格雷无HRPR组109例和氯吡格雷伴HRPR组107例。
- 主要终点为SPECT测定的心肌挽救指数(MSI)。
主要发现
- 最终TIMI 0/1血流发生率在普拉格雷组、氯吡格雷无HRPR组和氯吡格雷伴HRPR组分别为0.9%、1.8%和7.5%(P = .002)。
- TIMI心肌灌注分级0/1发生率在三组分别为19.8%、29.4%和41.1%(P = .0002)。
- MSI在三组分别为48%(27-66)、44%(30-72)和36%(15-55),P = .006。
临床怎么用
- 对接受直接PCI的STEMI患者,可考虑评估高残留血小板反应性以识别氯吡格雷反应不佳者。
- 伴HRPR的患者选用普拉格雷可能有助于提高心肌挽救。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of prasugrel over clopidogrel on myocardial salvage in ST-segment-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (p-PCI) is not fully elucidated. METHODS: Among 854 consecutive STEMI patients who underwent p-PCI, 446 patients were evaluated by two-phase (7 days and 3 months) single-photo emission computed tomography (SPECT). Patients were divided into two groups based on the loading P2Y12 inhibitor. The clopidogrel group was further divided based on the result of platelet function testing. Thus, the prasugrel group included 227 patients; the clopidogrel without high-residual platelet reactivity (HRPR) group, 109 patients; and the clopidogrel with HRPR group, 107 patients. The primary endpoint was the Myocardial Salvage Index (MSI), determined by SPECT. RESULTS: The incidence of final TIMI 0/1 and TIMI myocardial perfusion grade 0/1 was higher in the clopidogrel with HRPR group (0.9%, 1.8%, and 7.5%, P = .002; 19.8%, 29.4%, and 41.1%, P = .0002, in the prasugrel, clopidogrel without HRPR, and clopidogrel with HRPR groups, respectively). The MSI was significantly lower in the clopidogrel with HRPR group (48% [27-66], 44% [30-72], and 36% [15-55], P = .006, respectively). CONCLUSIONS: Prasugrel in STEMI patients was associated with an increased MSI compared with clopidogrel in the presence of HRPR.
引用
- Yoshida R, Takagi K, Ishii H, et al. Myocardial salvage after ST-segment-elevation myocardial infarction: comparison between prasugrel and clopidogrel in the presence or absence of high-residual platelet reactivity. J Nucl Cardiol. 2019. PMID: 31428979. doi:10.1007/s12350-019-01852-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。